Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05242861
Recruiting Observational

Retrospective Study of Brachytherapy

NCT05242861 · tracked via the Priya Life Science China tracker
Sponsor
Zhejiang Cancer Hospital
Phase
Observational
Started
2022-02-20
Last updated
2022-02-16

Condition(s) studied

BrachytherapyUterine Cervical NeoplasmsUterine NeoplasmsVulvar CancerVaginal CancerOvarian NeoplasmsGynecologic Neoplasm

Investigational drug(s) / intervention(s)

Brachytherapy

Brachytherapy: Applicator, dose, schedule, technology, image, 3D print, efficacy, toxicity of brachytherapy

Study summary

Brachytherapy for gynecological cancers will be studied retrospectively.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * 18 - 80 female * Underwent brachytherapy * With gynecological cancer Exclusion Criteria: * Refusal to enter this trial

Primary outcome measure(s)

  • Overall survival rate — 5-year
    the percentage of participants in the group who survives

Trial sites (1)

FacilityCityRegionStatus
Zhejiang Cancer Hospital Hangzhou Zhejiang Recruiting

More Zhejiang Cancer Hospital trials in China

Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer Recruiting
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity Recruiting
Radiotherapy Combined With Endostatin and Capecitabine for NPC Recruiting
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma Recruiting
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC Recruiting

Other trials for the same condition

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma Recruiting
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors Recruiting
A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration Recruiting
Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery Recruiting
Patient Journey in Advanced Gynecologic Cancers Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05242861 on ClinicalTrials.gov ↗ ← All trials in China